Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 4 57-4, 2005, Pages

  Hohenstein, Bernd ^a   Daniel, Christoph ^a   Wagner, Andrea ^a   Stasch, Johannes Peter ^b   Hugo, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Anti Thy1 model; BAY 41 2272; Matrix expansion

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; PYRAZOLONE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FIBROSIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; RAT;

EID: 15044363848     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00280.2004     Document Type: Article

References (39)

1. Arnold WP, Mittal CK, Katsuki S, and Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74: 3203-3207, 1977.
2. Bagchus WM, Jeunink MF, Rozing J, and Elema JD. A monoclonal antibody against rat platelets. I. Tissue distribution in vitro and in vivo. Clin Exp Immunol 75: 317-323, 1989.
3. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, and Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental proliferative nephritis. J Clin Invest 94: 2105-2116, 1994.
4. Baylis C, Mitruka B, and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, and Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107: 686-689, 2003.
6. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
7. El Nahas AM, Bassett AH, Cope GH, and Le Carpentier JE. Role of growth hormone in the development of experimental renal scarring. Kidney Int 40: 29-34, 1991.
8. Eng E, Floege J, Young BA, Couser WG, and Johnson RJ. Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? Kidney Int Suppl 45: S45-S47, 1994.
9. Ferrario R, Takahashi K, Fogo A, Badr KF, and Munger KA. Consequences of acute nitric oxide synthesis inhibition in experimental glomerulonephritis. J Am Soc Nephrol 4: 1847-1854, 1994.
10. Hobbs AJ and Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul Pharmacol 40: 149-154, 2003.
11. Hughes J, Brown P, and Shankland SJ. Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial cell proliferation following ureteric obstruction. Am J Physiol Renal Physiol 277: F948-F956, 1999.
12. Hugo C, Pichler R, Meek R, Gordon K, Kyriakides T, Floege J, Bornstein P, Couser WG, and Johnson RJ. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int 48: 1846-1856, 1995.
13. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, and Johnson RJ. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147: 1715-1727, 1995.
14. Jefferson JA and Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 12: 297-307, 1999.
15. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int 45: 1769-1782, 1994.
16. Johnson RJ. Platelets in inflammatory glomerular injury. Semin Nephrol 11: 276-284, 1991.
17. Keil A, Blom IE, Goldschmeding R, and Rupprecht HD. Nitrix oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int 62: 401-411, 2002.
18. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, and Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399, 2000.
19. Koesling D and Friebe A. Soluble guanylyl cyclase: structure and regulation. Rev Physiol Biochem Pharmacol 135: 41-65, 1999.
20. Lewko B and Stepinski J. Cyclic GMP signaling in podocytes. Microsc Res Tech 57: 232-235, 2002.
21. Moncada S, Palmer RM, and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
22. Mundel P, Gambaryan S, Bachmann S, Koesling D, and Kriz W. Immunolocalization of soluble guanylyl cyclase subunits in rat kidney. Histochem Cell Biol 103: 75-79, 1995.
23. Narita I, Border WA, Ketteler M, and Noble NA. Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72: 17-24, 1995.
24. Pilz RB and Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 93: 1034-1046, 2003.
25. Poczatek MH, Hugo C, Darley-Usmar V, and Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-β bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 157: 1353-1363, 2000.
26. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, and Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303, 1992.
27. Ruoslahti E, Hayman EG, Pierschbacher M, and Engvall E. Fibronectin: purification, immunochemical properties, and biological activities. Methods Enzymol 82: 803-831, 1982.
28. Rupprecht HD, Akagi Y, Keil A, and Hofer G. Nitric oxide inhibits growth of glomerular mesangial cells: role of the transcription factor EGR-1. Kidney Int 57: 70-82, 2000.
29. Sandau K, Pfeilschifter J, and Brune B. The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. J Immunol 158: 4938-4946, 1997.
30. Schleicher E and Wieland OH. Evaluation of the Bradford method for protein determination in body fluids. J Clin Chem Clin Biochem 16: 533-534, 1978.
31. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, and Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135: 333-343, 2002.
32. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215, 2001.
33. Stasch JP, Dembowsky K, Perzborn E, Stahl E, and Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135: 344-355, 2002.
34. Takamitsu Y, Nakanishi T, Nishihara F, Hasuike Y, Izumi M, Inoue T, Hiraoka K, Itahana R, and Miyagawa K. A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two β-blocking drugs, nipradilol and propranolol. Nephron Physiol 93: p42-50, 2003.
35. Theilig F, Bostanjoglo M, Pavenstadt H, Grupp C, Holland G, Slosarek I, Gressner AM, Russwurm M, Koesling D, and Bachmann S. Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol 12: 2209-2220, 2001.
36. Trachtman H, Futterweit S, and Singhal P. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun 207: 120-125, 1995.
37. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, and Dousa TP. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isoenzymes types III and IV. J Clin Invest 98: 262-270, 1996.
38. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, and Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 277: 9880-9888, 2002.
39. Westerhuis R, van Straaten SC, van Dixhoorn MG, van Rooijen N, Verhagen NA, Dijkstra CD, de Heer E, and Daha MR. Distinctive roles of neutrophils and monocytes in anti-Thy-1 nephritis. Am J Pathol 156: 303-310, 2000.